Brief: Pherecydes Pharma Partners With Spain's Navarrabiomed
31/03/2022 06:02
March 31 (Reuters) - PHERECYDES PHARMA SA ALPHE.PA :
* PHERECYDES PHARMA ANNOUNCES PARTNERSHIP WITH NAVARRABIOMED
TO
EVALUATE ITS ANTI-S. AUREUS PHAGES IN A NEW INDICATION
* OBJECTIVE OF NAVARRABIOMED RESEARCH TEAM IS TO TEST
PHERECYDES
PHARMA'S PHAGES ON A PORCINE MODEL OF S. AUREUS ENDOCARDITIS
* SPANISH BIOMEDICAL CENTER TO STUDY BENEFITS OF PHERECYDES
PHARMA'S PHAGES IN ANIMAL MODELS OF INFECTIOUS ENDOCARDITIS
Source text for Eikon: ID:nBw4nvYCla
Further company coverage: ALPHE.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 587 696 600;))
Recent news on Pherecydes Pharma SA
See all newsBrief: Erytech And Pherecydes Announce Merger And Name Change To Phaxiam Therapeutics
Brief: Pherecydes Pharma SA - Pherecydes Pharma And Erytech Pharma Shareholders Approve Merger Between Two Companies To Create Phaxiam Therapeutics
Brief: Erytech Announces That The Commercial Court Has Rejected Akkadian's Request To Postpone The Vote On The Merger With Pherecydes Pharma
Brief: Erytech: urges shareholders to vote for merger with Pherecydes and dismisses Akkadian's moves
Brief: Erytech Pharma Says Akkadian Has Initiated Proceedings To Postpone Vote On Merger With Pherecydes